Translational cancer research: Balancing prevention and treatment to combat cancer globally

Journal of the National Cancer Institute

Volumn 107, Issue 1, 2015, Pages

  Wild, Christopher P ^a   Bucher, John R ^b   De Jong, Bas W D ^c   Dillner, Joakim ^d   Von Gertten, Christina ^d   Groopman, John D ^e   Herceg, Zdenko ^a   Holmes, Elaine ^f   Holmila, Reetta ^a   Olsen, Jørgen H ^g   Ringborg, Ulrik ^h   Scalbert, Augustin ^a   Shibata, Tatsuhiro ⁱ   Smith, Martyn T ^j   Ulrich, Cornelia ^k   Vineis, Paolo ^f   McLaughlin, John ^l  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d KAROLINSKA INSTITUTE   (Sweden)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^l UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CONTROL; CANCER PREVENTION; CANCER RESEARCH; DEVELOPING COUNTRY; HUMAN GENOME PROJECT; KNOWLEDGE; MEDICAL TECHNOLOGY; PRIORITY JOURNAL; PUBLICATION; REVIEW; RISK REDUCTION; TRANSLATIONAL RESEARCH; DEVELOPED COUNTRY; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; FINANCIAL MANAGEMENT; HEALTH; HUMAN; INTERDISCIPLINARY COMMUNICATION; NEOPLASMS; STATISTICS AND NUMERICAL DATA; TRENDS;

DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; EARLY DETECTION OF CANCER; EVIDENCE-BASED MEDICINE; GLOBAL HEALTH; HUMANS; INTERDISCIPLINARY COMMUNICATION; NEOPLASMS; RESEARCH SUPPORT AS TOPIC; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84924502706     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju353     Document Type: Review

References (53)

1. Dancey JE, Bedard PL, Onetto N, Hudson TJ. The genetic basis for cancer treatment decisions. Cell. 2012;148(3):409-420.
2. Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011;11(10):726-734.
3. Chin L, Andersen JN, Futreal PA. Cancer genomics: from discovery science to personalized medicine. Nat Med. 2011;17(3):297-303.
4. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-2917.
5. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132(5):1133-1145.
6. Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011;12(10):933-980.
7. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol. 2012;13(8):790-801.
8. Farmer P, Frenk J, Knaul FM, et al. Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet. 2010;376(9747):1186-1193.
9. Alwan A. Global status report on noncommunicable diseases 2010. World Health Organization; 2011.
10. Vineis P, Wild CP. Global cancer patterns: causes and prevention. Lancet. 2014;383(9916):549-557.
11. Varmus H, Trimble EL. Integrating cancer control into global health. Sci Transl Med. 2011;3(101):101cm28.
12. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst. 1981;66(6):1191-1308.
13. Peto J. Cancer epidemiology in the last century and the next decade. Nature. 2001;411(6835):390-395.
14. Colditz GA, Sellers TA, Trapido E. Epidemiology - identifying the causes and preventability of cancer? Nat Rev Cancer. 2006;6(1):75-83.
15. Parkin DM, Boyd L, Walker LC. 16. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. Br J Cancer. 2011;105(Suppl 2):S77-S81.
16. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ. 2004;328(7455):1519.
17. Pirie K, Peto R, Reeves GK, Green J, Beral V. The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK. Lancet. 2013;381(9861):133-141.
18. Chang MH, You SL, Chen CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst. 2009;101(19):1348-1355.
19. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-ofstudy analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):89-99.
20. Cogliano VJ, Baan R, Straif K, et al. Preventable exposures associated with human cancers. J Natl Cancer Inst. 2011;103(24):1827-1839.
21. Croswell JM, Ransohoff DF, Kramer BS. Principles of cancer screening: lessons from history and study design issues. Semin Oncol. 2010;37(3):202-215.
22. Independent UK panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;380(9855):1778-1786.
23. Paci E. Summary of the evidence of breast cancer service screening outcomes in Europe and first estimate of the benefit and harm balance sheet. J Med Screen. 2012;19(Suppl 1):5-13.
24. Spitz MR, Bondy ML. The evolving discipline of molecular epidemiology of cancer. Carcinogenesis. 2010;31(1):127-134.
25. Ogino S, Lochhead P, Chan AT, et al. Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol. 2013;26(4):465-484.
26. Wild CP. Complementing the genome with an "exposome": the outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol Biomarkers Prev. 2005;14(8):1847-1850.
27. Rappaport SM, Smith MT. Epidemiology. Environment and disease risks. Science. 2010;330(6003):460-461.
28. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333(6046):1157-1160.
29. McHale CM, Zhang L, Lan Q, et al. Global gene expression profiling of a population exposed to a range of benzene levels. Environ Health Perspect. 2011;119(5):628-634.
30. Tilley AE, O'Connor TP, Hackett NR, et al. Biologic phenotyping of the human small airway epithelial response to cigarette smoking. PLoS One. 2011;6(7):e22798.
31. Beane J, Vick J, Schembri F, et al. Characterizing the impact of smoking and lung cancer on the airway transcriptome using RNA-Seq. Cancer Prev Res (Phila). 2011;4(6):803-817.
32. Ritchie SA, Tonita J, Alvi R, et al. Low-serum GTA-446 antiinflammatory fatty acid levels as a new risk factor for colon cancer. Int J Cancer. 2013;132(2):355-362.
33. Heinzmann SS, Brown IJ, Chan Q, et al. Metabolic profiling strategy for discovery of nutritional biomarkers: proline betaine as a marker of citrus consumption. Am J Clin Nutr. 2010;92(2):436-443.
34. Begg CB, Zabor EC, Bernstein JL, et al. A conceptual and methodological framework for investigating etiologic heterogeneity. Stat Med. 2013;32(29):5039-5052.
35. Campbell PT, Jacobs ET, Ulrich CM, et al. Case-control study of overweight, obesity, and colorectal cancer risk, overall and by tumor microsatellite instability status. J Natl Cancer Inst. 2010;102(6):391-400.
36. Yang XR, Chang-Claude J, Goode EL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011;103(3):250-263.
37. Hogervorst JG, de Bruijn-Geraets D, Schouten LJ, et al. Dietary acrylamide intake and the risk of colorectal cancer with specific mutations in KRAS and APC. Carcinogenesis. 2014;35(5):1032-1038.
38. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339(6127):1546-1558.
39. Kreso A, O'Brien CA, van GP, et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science. 2013;339(6119):543-548.
40. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer. 2012;12(5):323-334.
41. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012;13(5):518-527.
42. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer. 2006;6(2):130-140.
43. Mathers JC, Strathdee G, Relton CL. Induction of epigenetic alterations by dietary and other environmental factors. Adv Genet. 2010;71:3-39.
44. Auerbach SS, Shah RR, Mav D, et al. Predicting the hepatocarcinogenic potential of alkenylbenzene flavoring agents using toxicogenomics and machine learning. Toxicol Appl Pharmacol. 2010;243(3):300-314.
45. Thomas R, Thomas RS, Auerbach SS, Portier CJ. Biological networks for predicting chemical hepatocarcinogenicity using gene expression data from treated mice and relevance across human and rat species. PLoS One. 2013;8(5):e63308.
46. Thun MJ, Hoover RN, Hunter DJ. Bigger, better, sooner-scaling up for success. Cancer Epidemiol Biomarkers Prev. 2012;21(4):571-575.
47. Manolio TA, Weis BK, Cowie CC, et al. New models for large prospective studies: is there a better way? Am J Epidemiol. 2012;175(9):859-866.
48. Merlo DF, Wild CP, Kogevinas M, Kyrtopoulos S, Kleinjans J. NewGeneris: a European study on maternal diet during pregnancy and child health. Cancer Epidemiol Biomarkers Prev. 2009;18(1):5-10.
49. Walker CL, Ho SM. Developmental reprogramming of cancer susceptibility. Nat Rev Cancer. 2012;12(7):479-486.
50. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415-421.
51. Liotta LA, Petricoin EF III. -Omics and cancer biomarkers: link to the biological truth or bear the consequences. Cancer Epidemiol Biomarkers Prev. 2012;21(8):1229-1235.
52. Mwenifumbo JC, Marra MA. Cancer genome-sequencing study design. Nat Rev Genet. 2013;14(5):321-332.
53. World Economic Forum and Harvard School of Public Health. The Global Economic Burden of Non-Communicable Diseases. 2011. World Economic Forum. Ref Type: Report.